Daniel Shepshelovich

2.2k total citations
93 papers, 1.2k citations indexed

About

Daniel Shepshelovich is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Economics and Econometrics. According to data from OpenAlex, Daniel Shepshelovich has authored 93 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 17 papers in Economics and Econometrics. Recurrent topics in Daniel Shepshelovich's work include Health Systems, Economic Evaluations, Quality of Life (14 papers), Statistical Methods in Clinical Trials (9 papers) and Meta-analysis and systematic reviews (8 papers). Daniel Shepshelovich is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (14 papers), Statistical Methods in Clinical Trials (9 papers) and Meta-analysis and systematic reviews (8 papers). Daniel Shepshelovich collaborates with scholars based in Israel, Canada and United States. Daniel Shepshelovich's co-authors include Anat Gafter‐Gvili, Benaya Rozen‐Zvi, Tomer Avni, Noam Tau, Uzi Gafter, Hadar Goldvaser, Dafna Yahav, Yehuda Shoenfeld, Talia Diker‐Cohen and Eitan Amir and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Internal Medicine and PLoS ONE.

In The Last Decade

Daniel Shepshelovich

89 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Shepshelovich Israel 20 218 206 204 171 134 93 1.2k
Andrew J. Innes United Kingdom 21 218 1.0× 135 0.7× 174 0.9× 214 1.3× 158 1.2× 84 1.3k
G. Aulagner France 18 240 1.1× 119 0.6× 141 0.7× 126 0.7× 110 0.8× 79 1.2k
Clarence Lam China 19 245 1.1× 364 1.8× 346 1.7× 207 1.2× 163 1.2× 42 1.4k
Sara K. Tedeschi United States 28 165 0.8× 230 1.1× 160 0.8× 239 1.4× 134 1.0× 111 2.2k
Adriana Ceci Italy 25 370 1.7× 204 1.0× 164 0.8× 149 0.9× 365 2.7× 101 2.1k
Jan van Wijngaarden Netherlands 18 321 1.5× 157 0.8× 133 0.7× 289 1.7× 258 1.9× 35 2.0k
Lauren C. Bylsma United States 18 172 0.8× 221 1.1× 311 1.5× 93 0.5× 232 1.7× 43 1.2k
M. Longy‐Boursier France 15 176 0.8× 86 0.4× 380 1.9× 150 0.9× 136 1.0× 80 1.4k
Ulrike M. Reiss United States 19 552 2.5× 267 1.3× 215 1.1× 453 2.6× 212 1.6× 56 1.7k
Raj Patel United Kingdom 22 366 1.7× 90 0.4× 73 0.4× 204 1.2× 279 2.1× 71 1.7k

Countries citing papers authored by Daniel Shepshelovich

Since Specialization
Citations

This map shows the geographic impact of Daniel Shepshelovich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Shepshelovich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Shepshelovich more than expected).

Fields of papers citing papers by Daniel Shepshelovich

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Shepshelovich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Shepshelovich. The network helps show where Daniel Shepshelovich may publish in the future.

Co-authorship network of co-authors of Daniel Shepshelovich

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Shepshelovich. A scholar is included among the top collaborators of Daniel Shepshelovich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Shepshelovich. Daniel Shepshelovich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shepshelovich, Daniel, et al.. (2025). Heterogeneity of Primary Outcomes in Large Atherosclerotic Cardiovascular Disease Trials Published in Prominent Medical Journals. JAMA Internal Medicine. 185(4). 464–464. 1 indexed citations
2.
Amir, Eitan, Mark E. Robson, Nour Abuhadra, et al.. (2024). The impact of previous therapy on overall-survival in registration clinical trials for 1st line metastatic breast cancer a systemic review. Critical Reviews in Oncology/Hematology. 202. 104455–104455.
3.
Giladi, Moshe, Kenneth Hennrick, & Daniel Shepshelovich. (2023). Massive splenomegaly. European Journal of Internal Medicine. 114. 124–125. 1 indexed citations
4.
Veitch, Zachary, Daniel Shepshelovich, Zhihui Amy Liu, et al.. (2022). Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using PRO-CTCAE. British Journal of Cancer. 127(9). 1629–1635. 7 indexed citations
5.
Veitch, Zachary, Daniel Shepshelovich, Lisa Wang, et al.. (2021). Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials. JNCI Journal of the National Cancer Institute. 113(8). 980–988. 40 indexed citations
6.
Shepshelovich, Daniel, Noam Barda, Hadar Goldvaser, et al.. (2021). Incidence of lung cancer following pneumonia in smokers: a population-based study. QJM. 115(5). 287–291. 4 indexed citations
7.
Tau, Noam, Dafna Yahav, & Daniel Shepshelovich. (2020). Vaccine safety – is the SARS-CoV-2 vaccine any different?. Human Vaccines & Immunotherapeutics. 17(5). 1322–1325. 6 indexed citations
8.
Amir, Eitan, Ariadna Tibau, Rinat Yerushalmi, et al.. (2020). National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study. Cancer Treatment Reviews. 91. 102113–102113. 5 indexed citations
9.
Goldvaser, Hadar, Daniel Shepshelovich, Rinat Yerushalmi, et al.. (2019). Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis. JNCI Cancer Spectrum. 3(2). pkz033–pkz033. 16 indexed citations
10.
Chen, Lina, Lisa Wang, Anna Spreafico, et al.. (2019). Characterization and outcomes of patients enrolled to multiple phase I cancer trials. Cancer Chemotherapy and Pharmacology. 85(2). 469–472. 1 indexed citations
11.
Shepshelovich, Daniel, Ariadna Tibau, Hadar Goldvaser, et al.. (2019). Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials. Mayo Clinic Proceedings. 94(1). 74–83. 7 indexed citations
12.
Gafter‐Gvili, Anat, Ariadna Tibau, Pia Raanani, & Daniel Shepshelovich. (2019). Safety-Related Postmarketing Modifications of Drugs for Hematological Malignancies. Acta Haematologica. 143(1). 73–77. 2 indexed citations
13.
Tau, Noam, Liat Shargian, Mical Paul, et al.. (2019). Reporting infections in clinical trials of patients with haematological malignancies. Clinical Microbiology and Infection. 25(12). 1494–1500. 13 indexed citations
14.
Shepshelovich, Daniel, Amanda Townsend, Osvaldo Espin‐Garcia, et al.. (2018). Fc‐gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. Cancer Medicine. 7(11). 5478–5487. 20 indexed citations
15.
Vaxman, Iuliana, et al.. (2018). Agranulocytosis Associated with Waldenström Macroglobulinemia. Acta Haematologica. 140(1). 42–45.
16.
Klein, Alina, Daniel Shepshelovich, Galia Spectre, et al.. (2017). Screening for occult cancer in idiopathic venous thromboembolism — Systemic review and meta-analysis. European Journal of Internal Medicine. 42. 74–80. 10 indexed citations
17.
Goldvaser, Hadar, Shulamit Rizel, Daniel Hendler, et al.. (2016). The Association between Angiotensin Receptor Blocker Usage and Breast Cancer Characteristics. Oncology. 91(4). 217–223. 4 indexed citations
18.
Shepshelovich, Daniel, Alina Klein, Tzippy Shochat, et al.. (2016). Yield of workup for patients with idiopathic presentation of the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Internal Medicine. 32. 60–64. 5 indexed citations
19.
Shepshelovich, Daniel, Ron Ram, Orit Uziel, et al.. (2015). MicroRNA signature is indicative of long term prognosis in diffuse large B-cell lymphoma. Leukemia Research. 39(6). 632–637. 13 indexed citations
20.
Uziel, Orit, Gil Kanfer, Einat Beery, et al.. (2014). The effects of erythropoietin signaling on telomerase regulation in non-erythroid malignant and non-malignant cells. Biochemical and Biophysical Research Communications. 450(1). 274–282. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrew J. Innes Breakdown of academic impact, for papers by G. Aulagner Breakdown of academic impact, for papers by Clarence Lam Breakdown of academic impact, for papers by Sara K. Tedeschi Breakdown of academic impact, for papers by Adriana Ceci Breakdown of academic impact, for papers by Jan van Wijngaarden Breakdown of academic impact, for papers by Lauren C. Bylsma Breakdown of academic impact, for papers by M. Longy‐Boursier Breakdown of academic impact, for papers by Ulrike M. Reiss Breakdown of academic impact, for papers by Raj Patel
Rankless by CCL
2026